Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial
In this study (n=130), maintenance gemcitabine was associated with improved progression-free survival compared to supportive care alone (median 6.2 months [95% CI 4.6-8.7] vs 3.2 months [2.8-4.1]; HR 0.48 [95% CI 0.33–0.71]; p=0.0002).
Source:
The Lancet Respiratory Medicine